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ErbB signaling pathway 
A B S T R A C T   
A growing amount of evidence has revealed that long noncoding RNAs (lncRNAs) play significant roles in ma-
lignancies through different mechanisms especially the competing endogenous RNA (ceRNA). They have also 
been shown to have the potential diagnostic, prognostic and therapeutic biomarker capacity in oncology 
research. Recently, lncRNA Alu-mediated p21 transcriptional regulator (APTR) has been proposed as an onco-
genic lncRNA in development and clinical outcome of some cancers. However, clinical and molecular importance 
in breast cancer (BC) is still unclear. The purpose of this study was to examine the APTR expression and its 
potential roles in BC. The 47 BC tumors and 47 tumor adjacent normal tissues were obtained from the study 
subjects. Real-time PCR was applied for the analysis of APTR expression in breast tumors compared with paired 
adjacent normal tissues. Then, we used bioinformatics approach to investigate the potential ceRNA activity of 
APTR in APTR-microRNAs-mRNAs axes and with focus on ErbB signaling pathway in BC. Our results demon-
strated that APTR expression was significantly upregulated in BC tumors compared with the adjacent normal 
tissues. Besides, APTR over-expression was related to a larger tumors size. Finally, bioinformatics analysis 
indicated that APTR could influence cell proliferation through dysregulating the oncogenes working in ErbB 
signaling pathway by sponging some tumor suppressive microRNAs (miRNAs). Current work provided some 
clues for the involvement of APTR in physiopathology of the breast tumors. However, other aspects of these 
findings need to be further elucidated by future functional studies.   
1. Introduction 
Breast cancer (BC) is the most frequent malignancy among women 
worldwide (Bray et al., 2018). Although many studies have focused on 
BC pathobiology, detection and treatment, it still remains a health 
challenge issue for women (Turashvili and Brogi, 2017). Biomedical 
data suggest that the root cause of this problem is due to the heteroge-
neous phenotype of breast tumors and solving the problem requires 
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revealing specific molecular changes behind its different phenotypes 
(Turashvili and Brogi, 2017; Ellsworth et al., 2017). Because of this, 
various recent works on BC have focused on recent discoveries about the 
genome function to find key relevant clues (Low et al., 2018). Interest-
ingly, ENCODE (Encyclopedia of DNA Elements) project exposed that 
the majority of the human genome is transcribed as non-coding RNAs 
(Consortium EP, 2012). And more importantly, there is body of evidence 
that in addition to abnormal expression of coding transcripts, BC tumor 
cells show remarkably altered expression patterns of various types of 
non-coding RNAs compared with normal condition (Klinge, 2018). 
Among these dysregulated transcripts, long noncoding RNAs (lncRNAs) 
have been demonstrated to play pivotal roles in BC development and 
progression through acting in multiple ways (Zhang et al., 2019). 
lncRNAs are a subgroup of non-coding RNAs with >200 nucleotides 
in length which do not have the capacity to produce protein. These RNAs 
have emerged as one of the important expression regulators of the other 
genes by both transcriptional and post-transcriptional mechanisms 
(Yoon et al., 2013). And due to the advent of high-throughput 
sequencing methods, thousands of lncRNAs have been proved to be 
involved in various physiological and pathological conditions (Chiu 
et al., 2018). Recently, increasing evidence suggests that lncRNAs are 
involved in cancer initiation and progression by acting as competing 
endogenous RNAs (ceRNAs) in molecular networks which connect the 
function of mRNAs with that of noncoding RNAs (Salmena et al., 2011; 
Abdollahzadeh et al., 2019). In these networks, lncRNAs execute their 
roles as microRNAs (miRNA) sponges via carrying miRNA response 
element and consequently result in suppressing miRNAs function 
through lncRNA/miRNA/mRNA axes (Abdollahzadeh et al., 2019). One 
example is alu-mediated p21 transcriptional regulator (APTR) lncRNA 
which is located at 7q21 with 2303 nucleotides in length. Evidence 
exists that APTR acts as a suppressor of p21 expression through 
recruiting the polycomb repressive complex 2 (PRC2) to the p21 pro-
moter in human glioblastomas (Negishi et al., 2014). And newly, it is 
suggested that APTR/miR-132-3p/YAP1 axis contributes to osteosar-
coma cell proliferation, invasion and migration (Guan et al., 2019). 
Therefore, it is proposed that APTR expression is necessary for cell 
proliferation. 
However, its dysregulation and function in BC is still unclear. The 
aim of the present study was to compare the expression level of the APTR 
between paired breast tumor and normal adjacent tissue samples as well 
as evaluation of its expression with demographic and clinicopatholog-
ical characteristics of the BC patients. Finally, we adopted a bioinfor-
matics approach to investigate the potential APTR-miRNAs-mRNAs axes 
in BC through highlighting the ErbB signaling pathway. 
2. Material and methods 
2.1. Tissue sample collection from participants 
In the present study, 47 primary tumors and 47 paired adjacent 
normal tissues were obtained from the BC patients who had received 
neither chemotherapy nor radiotherapy before surgery from Shahid 
Faghihi hospital, Shiraz, Iran. Besides, 10 normal breast tissues, as 
calibrator samples, were collected from healthy women who undergone 
mammoplasty surgery. In order to implement suitable conditions for 
RNA extraction in later stages, fresh tissue specimens were immediately 
frozen in liquid nitrogen and were stored at − 80 ◦C. Notably, all tumor 
and paired normal tissues were confirmed by histopathological diag-
nosis. This study was approved by the local ethical committee at Shiraz 
University of Medical Sciences (Ethical Code: IR.FUMS.REC.1395.102). 
Written informed consent was also obtained from all subjects. A stan-
dard questionnaire was used for collection of the clinical and de-
mographic documents. Data about clinicopathological and demographic 
characteristics of the BC patients is shown in Table 1. 
2.2. Total RNA extraction and cDNA synthesis 
Total RNA was isolated by TRIzol reagent (Thermo Fisher) according 
to the manufacturer’s instructions and RNA integrity was assessed by gel 
electrophoresis. The extracted RNA samples were treated with DNase I 
(Takara, Japan) and their concentration and purity of the all treated 
RNAs was measured by NanoDrop ND-1000 Spectrometer (Thermo 
Scientific, Boston, MA). Moreover, the RNA integrity was confirmed by 
agarose gel electrophoresis. The cDNA synthesis assay was performed by 
Hyperscript™ kit from GeneAll (Korea, Cat.No: 601-005) according to 
the manufacturer’s instructions. 
2.3. Quantification of the levels of target lncRNAs by real time PCR 
The real-time PCR assay was conducted using BioFACT™ SYBR 
Green (cat no.: DQ383-40h, South Korea). The β2-microglobulin (B2M) 
gene was used as the housekeeping gene for normalizing data. The real 
time PCR reaction assays were accomplished in total reaction volume of 
20 μl reaction mixture comprising the 1 ng of cDNA, 5 pmol of each 
primer, and 10 μl of 2× SYBR Green PCR mix. Also, performance con-
ditions of thermal cycling included an initial stage of activation for 30s 
at 95 ◦C followed by 40 cycles at 95 ◦C for 20s and 60 ◦C for 30 s. All 
reactions were performed in duplicate. The sequences of primers for 
real-time PCR were APTR forward 5′-GGTAGTCGATTGATGGGAAGTG- 
3′, APTR reverse 5′-ATTCCACTGGCTCTTGTTCC-3′; B2M forward 5′- 
AGATGAGTATGCCTGCCGTG-3′, and B2M reverse 5′-GCGGCATCTT-
CAAACCTCCA-3′. The normal breast tissues were used as calibrator to 
Table 1 
Expression of APTR in relation to the clinicopathological and demographic 
variables of the patients. The bold font indicates a statistically significant 
assosiation  




Age <50  29  7.4  0.7 
≥50  18  4.7  
Tumor size ≤2  16  6.6  0.04 
2–4  22  4.3 
≥4  9  12.6 
Estrogen receptor Positive  42  4.7  0.6 
Negative  5  7.6  
Progesterone receptor Positive  32  4.5  0.1 
Negative  15  7.6 
HER2 Positive  19  5.9  0.5 
Negative  28  4.9  
Histological grade G1  12  7.8  0.07 
G2  22  5.5 
G3  13  3.8 
TNM stage 1/2  32  7.5  0.1 
3  15  3.8  
Lymph node metastasis Yes  27  7.4  0.5 
No  20  4.5 
Histologic type of invasive 
carcinoma 
IDC  45  5.3  
ACC  1  38.3  0.1 
ILC  1  0.5  
Age of menarche ≤13  27  4.5  0.7 
≥14  20  7.7  
Age of first full term pregnancy 
(FFTP) 
<25  32  5.1  0.7 
≥25  8  4.2 
Breastfeeding duration (month) NO  8  9.9  0.6 
≤6  8  3.2 
6–24  24  5.2 
≥24  7  7.4 
Menopausal status Pre  29  7.4  0.4 
Post  18  4.3  
Menopausal age <50  8  6.9  1.0 
≥50  10  3.3 
Family history of BC Positive  20  7.5  0.4 
Negative  27  4.7 
IDC: infiltrating ductal carcinoma, ACC: adenoid cystic carcinoma, ILC: invasive 
lobular carcinoma, BC: breast cancer. 
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obtain the relative threshold cycle (ΔCt), and the relative expression was 
calculated by 2− ΔΔCT method. 
2.4. Bioinformatics predictions 
In order to investigate upregulation of APTR gene in tumor tissues as 
far as competing endogenous RNAs (ceRNAs) is concerned, a bioinfor-
matics approach was applied. The workflow of bioinformatics analyses 
has been summarized in Fig. 1. In the first step, the experimentally 
validated APTR-miRNA interactions were assessed by LncBase version 2 
(Paraskevopoulou et al., 2012). We used the tools of LncBase database to 
survey the experimentally supported miRNA recognition elements 
(MREs) on desired lncRNAs derived from both available publications 
and the 153 AGO CLIP-Seq libraries. All complementary sites for seed 
region of miRNAs were detected in APTR sequence (Supplementary 
Fig. 1). Next, APTR/miRNAs/mRNAs networks in ErbB signaling 
pathway was constructed based on Tarbase (experimentally validated 
miRNA-mRNA interactions) (Karagkouni et al., 2017), DIANA mirPath 
(Vlachos et al., 2015), and miRmap (Vejnar et al., 2013) databases. It 
should be noted that the miRNA-mRNA interactions, which were ob-
tained from TarBase, have been validated by miRmap database in an 
attempt to reduce the number of false positive interactions. The mRNAs 
with more than two miRNA interactions were selected for further ana-
lyses and the extracted subnetwork was illustrated by cytoscape soft-
ware (Smoot et al., 2010). Finally, GEPIA web server was used to 
investigate expression of APTR and downstream genes in APTR/miR-
NAs/mRNAs axes in breast tumors compared with normal tissues based 
on the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expres-
sion (GTEx) data (Tang et al., 2017). Enrichr web server was used for 
functional annotation based on GO Biological Process 2018. P-value 
<0.05 was considered to be as significant enrichment (Kuleshov et al., 
2016). 
2.5. Statistical analysis 
In this study, statistical analyses were carried out by SPSS 21 soft-
ware package. Numerical values were presented as median and 95% 
confidence interval (CI) and qualitative data as frequency and percent-
age. The Mann–Whitney test was conducted to compare the APTR 
relative expression between tumor samples and paired adjacent normal 
tissues. The association between the expression of APTR and clinico-
pathological and demographic characteristics were calculated by t-test 
or ANOVA and alternative non-parametric tests. P-value less than 0.05 
was considered as a statistically significant level. 
3. Results 
3.1. APTR expression in tumor and paired normal tissues as well as its 
expression level in relation to clinicopathological and demographic 
characteristics of the patients 
As it is shown in Fig. 2A, the statistical evaluations showed that the 
levels of APTR were significantly higher in tumors (Median = 5.3) than 
normal samples (Median = 0.6) (P-value <0. 0001). In addition, 
Kruskal-Wallis Test indicated that increased expression of APTR is 
significantly associated with higher tumor size (Fig. 2B). In this study, 
APTR expression is not significantly related to other clinicopathological 
and demographic characteristics of the patients. Altough, increased 
expression of APTR shows a trend toward higher grade tumors, it is not 
statistically significance level (P-value = 0.07). The details of clinico-
pathological and demographic characteristics of the patients and the 
expression level of lncRNA APTR are summarized in Table 1. 
3.2. Bioinformatics prediction of potential APTR-miRNAs-mRNAs axes 
involved in ErbB signaling pathway APTR-miRNAs-mRNAs network 
We observed bioinformatically that APTR, as a miRNA sponging 
RNA, has several MREs on its own sequence. According to LncBase 
Experimental v.2 and DIANA miRpath, 12 ErbB signaling-related miR-
NAs could be sponged by APTR. Furthermore, based on Tarbase and 
miRmap, 31 ErbB signaling-related mRNAs are regulated by these 
miRNAs (Supplementary Fig. 2). When identifying a stronger APTR- 
miRNAs-mRNAs network, we found downstream genes that are poten-
tially regulated by more than two miRNAs. The achieved network 
indicated 10 miRNAs (miR-4328, miR-5006-3p, miR-26a-5p, miR-32- 
5p, miR-132-3p, miR-188-3p, miR-19a, miR-19b, miR-450b-5p and 
miR-139-5p) are not only targeting some ErbB signaling-related genes 
but also could be sponged by lncRNA APTR. Among them, miR-5006-3p 
and miR-4328 had three and two MREs on the APTR sequence, respec-
tively. The data obtained on these findings are shown in Fig. 3. In 
addition, we found that the five protein encoding genes including CRKL, 
MAP2K4, PTK2, ABL2 and GAB1 were downstream of the APTR- 
miRNAs-mRNAs axes and were potentially regulated by a set of miR-
NAs mentioned above. And finally, based on the TCGA and GTEx data, 
the expression analysis of APTR and its downstream genes in breast 
tumors compared with normal tissues showed that the APTR, CRKL, 
MAP2K4, PTK2 and ABL2 had a tendency toward higher expression in 
tumors, although this observation was not at a significant level (Sup-
plementary Fig. 3). 
Experimentally validated APTR-miRNAs interactions 
LncBase
Selecting miRNAs involved in ErbB signaling pathway 
TarBase, DIANA mirPath 
Validating miRNA-genes interactions  
miRmap 
Correlation between expression of APTR 






Investigation of APTR and downstream genes 
expression in breast tumors and normal 
tissues based on TCGA and GTEx data 
GEPIA 
Fig. 1. The workflow of bioinformatics analyses.  
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3.3. Functional annotation analysis 
Enrichr web server was used to investigate GO terms associations 
with five protein coding genes which are shown in Fig. 3 based on GO 
Biological Process 2018. Detailed results are summarized in Table 2. 
Results demonstrated that genes function in benefit of tumor prolifera-
tion and angiogenesis. 
4. Discussion 
Although significant advances have been made on various aspects of 
breast tumors, because of their wide heterogeneous phenotype they do 
not respond effectively to existing therapeutic interventions. For this 
reason, BC is still considered as a cancer with high mortality in women 
(Turashvili and Brogi, 2017; Ellsworth et al., 2017). Therefore, devel-
oping the effective therapeutic approaches for this cancer is urgently 
essential. Accumulating biomedical evidence has revealed that dysre-
gulation of lncRNAs is linked to pathophysiology of the BC and they also 
Fig. 2. A: The scatter plot of comparison of APTR expression between tumor samples and paired adjacent normal tissues. B: The boxplot of comparison of APTR 
expression between the different tumor size groups. P.value was calculated using the Mann–Whitney test. 
Fig. 3. The extracted axes from APTR/miRNAs/mRNAs network involved in ErbB signaling pathway, including mRNAs which show more than 2 interactions with 
miRNAs. The nodes in green represent microRNAs, the nodes in blue are mRNAs and node in red is lncRNA. The number of edges between APTR and miRNAs 
indicates number of complementary sites in APTR sequence for miRNA seed region. The number of edges between miRNA and mRNA indicates complementary sites 
in mRNA 3′UTR for miRNA seed region. 
Table 2 
Functional enrichment analysis of protein encoding genes including CRKL, 
MAP2K4, PTK2, ABL2 and GAB1 genes.  
Biological process GO ID P.value Combined 
Score 
ErbB signaling pathway 38127 6.30E− 07  21.31 
Positive regulation of cell migration by 
vascular endothelial growth factor 
signaling pathway 
38089 0.0019  21.69 
Epidermal growth factor receptor 
signaling pathway 
7173 2.30E− 07  33.13 
Regulation of substrate adhesion- 
dependent cell spreading 
1900024 4.20E− 05  17.19 
Vascular endothelial growth factor 
signaling pathway 
38084 0.0019  17.04 
Negative regulation of anoikis 2000811 0.0039  11.98 
Data have been achieved from Enrichr web server. GO: gene ontology. 
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have the potential to be promising diagnostic, prognostic biomarkers 
and therapeutic targets (Zhang et al., 2019). Accordingly, detailed un-
derstanding the role of lncRNAs and their mechanisms of function at 
both the transcriptional and translational levels during the BC 
tumourigenesis might help to further discover the biological features of 
the breast tumors as well as their clinical uses (Zhang et al., 2019; Arun 
and Spector, 2019). An interesting and recent discovery related to 
lncRNAs and BC cancer is the identification of dysregulated lncRNA- 
related ceRNA regulatory networks, in which lncRNAs act as a sponge 
for miRNAs regulating the protein-coding mRNAs in BC tumourigenesis 
and pathogenesis (Abdollahzadeh et al., 2019). According to the sug-
gestions of current BC research, these ceRNA networks appear to be key 
clues in characterizing the complex aspects of breast tumors, and so 
identifying more networks in BC may help in revealing how it molecu-
larly and clinically develops. In this regard, some novel dysregulated 
lncRNAs with ceRNA activity have been reported in the development of 
various cancers (Qi et al., 2019), however there is no data regarding 
them in BC (Negishi et al., 2014). 
Herein, we indicated an upregulated expression level of the lncRNA 
APTR in BC tumor tissues compared to paired adjacent normal tissues. In 
addition, our results revealed that this elevated expression of APTR is 
significantly linked to a larger tumor size. Previous data regarding the 
involvement of APTR in BC has not been reported. However, this 
observation in our study is in line with the previous works whose find-
ings have implied a potential oncogenic role of the APTR in some tu-
mors. For example, Negishi et al. (Yu et al., 2015) demonstrated that 
APTR represses p21 expression by recruiting the PRC2 complex to the 
p21 promoter in glioma cell lines. Moreover, APTR was upregulated and 
activated in hepatic stellate cells (HSCs) in fibrotic liver samples, and 
APTR silencing could inhibit cell cycle and proliferation in HSCs. In 
another study, a significant overexpression of the APTR in human os-
teosarcoma tissues and cell lines has been recently reported. And 
interestingly, this investigation indicated that lncRNA APTR contributes 
to osteosarcoma cell proliferation, invasion and migration through 
APTR/miR-132-3p/YAP1 ceRNA axis and APTR knockdown via siRNA 
resulted in the reduction of the cell proliferation, invasion and migration 
of the osteosarcoma cell lines (Guan et al., 2019). Therefore, based on 
our finding that the expression of APTR is elevated in BC as well as the 
above observations by various studies on its oncogenic roles in other 
cancers, it is thought that lncRNA APTR may function as an oncogene in 
key hallmarks of the BC, partly through via its ceRNA activity. 
Accordingly, we expanded its expression results into bioinformatics 
ceRNA function data, focusing on its role in important signaling path-
ways involved in BC, in particular as APTR/miRNAs/mRNAs network 
regulating ErbB signaling pathway. This signaling pathway is a well- 
known proliferative pathway in the BC development where several 
data have shown that ErbB receptor family and its downstream path-
ways have regulated cell proliferation, angiogenesis and migration 
(Hardy et al., 2010). The outputs of this analysis indicated that the 
lncRNA APTR may regulate five target downstream genes, including 
CRKL, MAP2K4, PTK2, ABL2 and GAB1 through APTR/miRNA/mRNA 
axis. Besides, through comparing the TCGA breast tumor data with 
TCGA and GTEx normal data, we observed that mRNAs of the APTR, 
CRKL, MAP2K4, PTK2 and ABL2 had a tendency toward higher 
expression level in tumors. In the next step, functional enrichment 
analysis for these protein encoding genes consistently confirmed their 
oncogenic roles in positive regulation of cell proliferation and migration 
as well as negative regulation of anoikis. 
Importantly, the CRKL gene produces an adapter protein that is 
thought to be an oncogene. It plays crucial roles in various cellular 
biological processes, including cell proliferation, adhesion and migra-
tion. The overexpression of CRKL is correlated with progression and 
malignant proliferation of human BC (Zhao et al., 2013). PTK2, a 
cytoplasmic protein tyrosine kinase, is over-expressed and activated in 
several solid tumors, including BC (Rigiracciolo et al., 2019). The pro-
tein product of the PTK2 controls invasion and cancer stem cell self- 
renewal (Sulzmaier et al., 2014). Another member of the target down-
stream set for APTR was the ABL2 gene, which encodes a non-receptor 
tyrosine kinase and plays a key role in cell proliferation. It is reported 
that activation of ABL2 in solid tumors is driven by its enhanced 
expression due to amplification (Greuber et al., 2013). Furthermore, 
ABL2 overexpression predicts poor prognosis and is linked to cancer cell 
migration and invasion in BC (He et al., 2019). Regarding the Grb2- 
associated binder 1 (GAB1), it is a docking protein that transduces 
proliferative signals from Met and EGFR tyrosine kinases. And the re-
ported evidence has indicated that the expression of GAB1 is signifi-
cantly increased in breast tumors compared to normal breast samples. 
Additionally, its elevated expression is positively linked with the 
metastasis in BC patients (Wang et al., 2019). Research results con-
cerning the mitogen-activated protein kinase kinase 4 (MAP2K4) have 
showed inconsistency data. Some studies have revealed its function as 
an oncogene in cancer progression and invasion (Hübner et al., 2018). 
However, a number of studies have found that MAP2K4 act as a tumor 
suppressor gene (Yamada et al., 2002). Consequently, these data high-
light the findings of the present study that the lncRNA APTR may play a 
weighty function in pathophysiology of the BC through interacting with 
these key cancer-related protein encoding genes. 
Additionally, our bioinformatics analysis found that 10 different 
miRNAs including the miR-4328, miR-5006-3p, miR-26a-5p, miR-32- 
5p, miR-132-3p, miR-188-3p, miR-19a, miR-19b, miR-450b-5p and 
miR-139-5p potentially target all the above ErbB signaling-related 
encoding genes, through binding to their seed regions on the relevant 
mRNAs. On the other hand, it was indicated that lncRNA APTR could 
sponge these miRNAs. Thus, this may reveal a potential APTR-miRNAs- 
mRNAs network in which the APTR acts as ceRNA for sponge of the 
miRNAs regulating downstream mRNAs whose works are to control 
ErbB signaling. It is also interesting to note that the lncRNA APTR had 
three MREs for miR-5006-3p and two MREs for miR-4328, implying a 
stronger sponging. Notably, evidence from previous research supports 
that miR-4328, miR-5006-3p, miR-26a-5p, miR-32-5p, miR-132-3p, 
miR-188-3p, miR-450b-5p and miR-139-5p are downregulated in 
different cancers, including BC (studies shown in Table 3). Furthermore, 
the interaction between APTR and miR-132-3p has functionally vali-
dated by luciferase assay in the osteosarcoma cell line in which APTR 
downregulates the miR-132-3p (Guan et al., 2019). Thus, based on these 
observations it is reasonable to suggest that these miRNAs have tumor 
suppressive roles in malignancies, and during the BC development, 
because of increased expression of lncRNA APTR and its oncogenic 
ceRNA function, expression of these miRNAs is reduced. 
Taken together, our experiment and bioinformatics results, in 
agreement with the supporting evidence from previous studies, suggest 
that lncRNA APTR is significantly upregulated in the breast tumors, and 
mechanistically, it may act as an oncogene in the development of BC 
through sponging the tumor suppressive miRNAs which controls the 
ErbB signaling pathway via its ceRNA activity. In turn, this results in 
upregulating the mRNAs of some oncogenes whose works are to boost 
ErbB signaling pathway. Most importantly, increased expression of the 
APTR and its downstream protein encoding genes regulating the mo-
lecular ErbB signaling pathway are linked to tumor cell proliferation. 
Thus, the association of APTR upregulation with tumor size in the pre-
sent study may be a reflection of such a molecular event, and this makes 
it to be a potential prognostic biomarker for breast tumors. Although 
further work needs to be carried out in order to better understand the 
detailed roles of each of the described components of the potential 
APTR/miRNAs/mRNAs ceRNA network in BC development. 
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